Filing Flows › Lineage Cell Therapeutics (LCTX) › Q2 2026 › vs Q2 2025
Lineage Cell Therapeutics (LCTX) Q2 2026 vs Q2 2025 (year over year)
Lineage Cell Therapeutics's revenue fell $1.7M (-61%) from $2.8M in Q2 2025 to $1.1M in Q2 2026. The biggest changes: Royalties License and Other Revenues −$107K (-46%).
Lineage Cell Therapeutics, Q2 2026: revenue $1.1M (-61% year over year), operating margin -834.7%, net earnings $1.5M, operating cash flow −$7.2M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Upfront License Fees | $600K | $2.5M | −$1.9M | -76% |
| Royalties License and Other Revenues | $126K | $233K | −$107K | -46% |
| Revenue | $1.1M | $2.8M | −$1.7M | -61% |
| Other income, net | $10.5M | −$10.6M | $21.1M | — |
| Costs & expenses | $11.5M | $33.1M | −$21.6M | -65% |
| Operating costs | $10.0M | $22.5M | −$12.6M | -56% |
| Net earnings | $1.5M | −$30.4M | $31.9M | — |
| Research & development | $4.8M | $3.1M | $1.7M | +54% |
| General & admin | $5.2M | $4.6M | $658K | +14% |
| Operating cash sources | $10.6M | −$23.4M | $34.0M | — |
| Depreciation & amortization | $187K | $171K | $16K | +9% |
| Share-based compensation | $1.6M | $1.2M | $363K | +29% |
| Cash used in operations | $7.2M | $5.5M | $1.7M | +31% |
| Working capital & other | $10.6M | −$23.4M | $34.0M | — |
Questions
How much did Lineage Cell Therapeutics's revenue grow year over year in Q2 2026?
Lineage Cell Therapeutics's revenue fell $1.7M (-61%) from $2.8M in Q2 2025 to $1.1M in Q2 2026.
What drove Lineage Cell Therapeutics's revenue change in Q2 2026?
Royalties License and Other Revenues −$107K (-46%).